272 related articles for article (PubMed ID: 24835494)
21. [HBV pol/S gene mutations in chronic hepatitis B patients receiving nucleoside/nucleotide analogues treatment].
Kırdar S; Yaşa MH; Sayan M; Aydın N
Mikrobiyol Bul; 2019 Apr; 53(2):144-155. PubMed ID: 31130119
[TBL] [Abstract][Full Text] [Related]
22. Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients.
Ramos B; Núñez M; Martín-Carbonero L; Sheldon J; Rios P; Labarga P; Romero M; Barreiro P; García-Samaniego J; Soriano V
J Acquir Immune Defic Syndr; 2007 Apr; 44(5):557-61. PubMed ID: 17224847
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis B virus genotype distribution and its lamivudine-resistant mutants in HIV-coinfected patients with chronic and occult hepatitis B.
Quarleri J; Moretti F; Bouzas MB; Laufer N; Carrillo MG; Giuliano SF; Pérez H; Cahn P; Salomon H
AIDS Res Hum Retroviruses; 2007 Apr; 23(4):525-31. PubMed ID: 17506609
[TBL] [Abstract][Full Text] [Related]
24. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene.
Torresi J; Earnest-Silveira L; Civitico G; Walters TE; Lewin SR; Fyfe J; Locarnini SA; Manns M; Trautwein C; Bock TC
Virology; 2002 Jul; 299(1):88-99. PubMed ID: 12167344
[TBL] [Abstract][Full Text] [Related]
25. Molecular Epidemiology of Hepatitis B Virus in Turkish Cypriot.
Sumer U; Sayan M
Pol J Microbiol; 2019 Dec; 68(4):449-456. PubMed ID: 31880889
[TBL] [Abstract][Full Text] [Related]
26. Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection.
Li X; Liu Y; Zhao P; Wang Y; Chen L; Xin S; Zhang XX; Xu D
Antivir Ther; 2015; 20(2):141-7. PubMed ID: 24992206
[TBL] [Abstract][Full Text] [Related]
27. Mutations associated with drug resistance and prevalence of vaccine escape mutations in patients with chronic hepatitis B infection.
Dos Santos MIMA; Pacheco SR; Stocker A; Schinoni MI; Paraná R; Reis MG; Silva LK
J Med Virol; 2017 Oct; 89(10):1811-1816. PubMed ID: 28500726
[TBL] [Abstract][Full Text] [Related]
28. [Polymerase region mutations and hepatitis B virus genotypes in chronic hepatitis B patients with poor response to lamivudine].
Xu LJ; Pan C; Li QG; Chen RH; Zheng L; Zhang QY; Chen HC
Zhonghua Gan Zang Bing Za Zhi; 2010 Mar; 18(3):180-3. PubMed ID: 20380793
[TBL] [Abstract][Full Text] [Related]
29. [Determination of hepatitis B virus genotype and detection of lamivudine-resistance mutations].
Nogales MC; Serrano MC; Suárez E; Corpas R; Pérez L; Claro R; Jarana R; Romero-Gómez M; Martín-Mazuelos E
Gastroenterol Hepatol; 2004 Nov; 27(9):515-20. PubMed ID: 15544736
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the
Arikan A; Sayan M; Sanlidag T; Suer K; Akcali S; Guvenir M
Pol J Microbiol; 2019 Sep; 68(3):317-322. PubMed ID: 31880877
[TBL] [Abstract][Full Text] [Related]
31. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.
Ohkawa K; Takehara T; Kato M; Deguchi M; Kagita M; Hikita H; Sasakawa A; Kohga K; Uemura A; Sakamori R; Yamaguchi S; Miyagi T; Ishida H; Tatsumi T; Hayashi N
J Infect Dis; 2008 Oct; 198(8):1150-8. PubMed ID: 18713056
[TBL] [Abstract][Full Text] [Related]
32. The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations.
Zhu Y; Curtis M; Borroto-Esoda K
Antivir Chem Chemother; 2011 Aug; 22(1):13-22. PubMed ID: 21860069
[TBL] [Abstract][Full Text] [Related]
33. [Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].
Sayan M; Hülagü S; Akhan SC; Sentürk O; Meriç M; Cekmen M
Mikrobiyol Bul; 2009 Jul; 43(3):425-32. PubMed ID: 19795617
[TBL] [Abstract][Full Text] [Related]
34. Frequent detection of hepatitis B virus variants associated with lamivudine resistance in treated South African patients infected chronically with different HBV genotypes.
Selabe SG; Song E; Burnett RJ; Mphahlele MJ
J Med Virol; 2009 Jun; 81(6):996-1001. PubMed ID: 19382250
[TBL] [Abstract][Full Text] [Related]
35. [HBV vaccine escape mutations in a chronic hepatitis B patient treated with nucleos(t)ide analogues].
Sayan M; Buğdacı MS
Mikrobiyol Bul; 2013 Jul; 47(3):544-9. PubMed ID: 23971933
[TBL] [Abstract][Full Text] [Related]
36. Epidemiology study of HBV genotypes and antiviral drug resistance in multi-ethnic regions from Western China.
Zhang Q; Liao Y; Chen J; Cai B; Su Z; Ying B; Lu X; Tao C; Wang L
Sci Rep; 2015 Nov; 5():17413. PubMed ID: 26612031
[TBL] [Abstract][Full Text] [Related]
37. Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes.
Mello FC; Fernandes CA; Gomes Sde A
Mem Inst Oswaldo Cruz; 2012 May; 107(3):317-25. PubMed ID: 22510826
[TBL] [Abstract][Full Text] [Related]
38. Effect of HIV co-infection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B.
Iacomi F; Vincenti D; Vairo F; Solmone M; Mariano A; Piselli P; Puro V; Capobianchi MR; Antonucci G
J Med Virol; 2009 Jul; 81(7):1151-6. PubMed ID: 19475624
[TBL] [Abstract][Full Text] [Related]
39. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
[TBL] [Abstract][Full Text] [Related]
40. Antiviral drug-associated potential vaccine-escape hepatitis B virus mutants in Turkish patients with chronic hepatitis B.
Sayan M; Akhan SC
Int J Infect Dis; 2011 Oct; 15(10):e722-6. PubMed ID: 21784687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
